Impact Biomedical (IBO) Stock Price, News & Analysis

Company Overview

Impact Biomedical, Inc. is a biotechnology and life sciences company focused on developing and commercializing biomedical technologies, pharmaceutical products and related health solutions. Its activities have included research into antiviral, antimicrobial and anti-inflammatory applications, with an emphasis on technologies intended to address infectious diseases and other public health needs.

The company has described a portfolio of biomedical intellectual property and development programs rather than a broad portfolio of established commercial products. Its work has included potential therapeutics, preventive technologies and other health-related applications developed independently or through research and commercialization relationships.

Impact Biomedical is publicly traded on the NYSE American under the symbol IBO. Publicly available information about its operating geographies, commercial scale and current leadership is limited, and the company appears to remain primarily focused on research, development and the potential commercialization of its technology portfolio.

Key Stats

• Today's Range: $4.13 to $4.39
• 50-Day Range: $4.11 to $7.45
• 52-Week Range: $4.06 to $10.47
• Volume: 4,014 shs
• Average Volume: 14,890 shs
• Market Capitalization: $36.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Impact Biomedical Stock Analysis - MarketRank™

Impact Biomedical scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Impact Biomedical.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Impact Biomedical has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.21% of the float of Impact Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Impact Biomedical has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Impact Biomedical has recently decreased by 94.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Impact Biomedical does not currently pay a dividend.

Dividend Growth

Impact Biomedical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Impact Biomedical this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Impact Biomedical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Impact Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

89.00% of the stock of Impact Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Impact Biomedical has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:IBO
• CIK: 1834105
• Web: www.impactbiomedinc.com
• Phone: (585) 232-1500
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.84 million
• Net Margins: 2,254.28%
• Pretax Margin: -5,154.29%
• Return on Equity: 8.81%
• Return on Assets: 4.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: $30 thousand
• Price / Sales: 1,209.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.88 per share
• Price / Book: 2.26

Miscellaneous

• Outstanding Shares: 8,540,000
• Free Float: 939,000
• Market Cap: $36.30 million
• Optionable: N/A
• Beta: 2.74